Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
REGN13089-M404-M2980
- Development stage
- Phase 2
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
REGN13089-M404-M2980 is an investigational MET-targeting antibody-drug conjugate (ADC) developed by Regeneron Pharmaceuticals. It consists of a biparatopic anti-MET antibody (REGN13089) conjugated via a transglutaminase-reactive linker (M404) to a camptothecin-based topoisomerase I inhibitor payload (M2980, such as ProDXd). By binding to the mesenchymal-epithelial transition factor (MET) receptor on the surface of tumor cells, the ADC is internalized, releasing the cytotoxic payload to induce DNA damage and cell death. REGN13089-M404-M2980 is being evaluated in Phase 1/2 clinical trials for the treatment of previously treated advanced solid tumors.
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)
Beyond the preview
Go deeper on REGN13089-M404-M2980.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on REGN13089-M404-M2980.